Cargando…

Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database

PURPOSE: To develop the clinical calculator for mortality of patients with metastatic renal cell carcinoma (mRCC) using Korean Renal Cancer Study Group (KRoCS) database. MATERIALS AND METHODS: Data from 1,115 patients with mRCC treated in 4 hospitals joining KRoCS between 1993 and 2016 were pooled....

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jae Young, Tae, Bum Sik, Jeong, Chang Wook, Song, Cheryn, Seo, Seong Il, Hong, Sung Kyu, Chung, Jinsoo, Hong, Sung-Hoo, Hwang, Eu Chang, Kwak, Cheol, Seo, Ill Young, Park, Suyeon, Park, Chanwang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Urological Association 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189103/
https://www.ncbi.nlm.nih.gov/pubmed/32377601
http://dx.doi.org/10.4111/icu.2020.61.3.260
_version_ 1783527438816378880
author Park, Jae Young
Tae, Bum Sik
Jeong, Chang Wook
Song, Cheryn
Seo, Seong Il
Hong, Sung Kyu
Chung, Jinsoo
Hong, Sung-Hoo
Hwang, Eu Chang
Kwak, Cheol
Seo, Ill Young
Park, Suyeon
Park, Chanwang
author_facet Park, Jae Young
Tae, Bum Sik
Jeong, Chang Wook
Song, Cheryn
Seo, Seong Il
Hong, Sung Kyu
Chung, Jinsoo
Hong, Sung-Hoo
Hwang, Eu Chang
Kwak, Cheol
Seo, Ill Young
Park, Suyeon
Park, Chanwang
author_sort Park, Jae Young
collection PubMed
description PURPOSE: To develop the clinical calculator for mortality of patients with metastatic renal cell carcinoma (mRCC) using Korean Renal Cancer Study Group (KRoCS) database. MATERIALS AND METHODS: Data from 1,115 patients with mRCC treated in 4 hospitals joining KRoCS between 1993 and 2016 were pooled. Five-year survival rates were calculated using Kaplan–Meier curve. A clinical calculator for 5-year mortality was developed using multivariable logistic regression analysis and validated externally using dataset including 916 patients from 4 other hospitals. RESULTS: Overall survival rates and cancer specific survival rate at 5 years were 28.5% and 29.4%, respectively. Among baseline factors, increased neutrophil-lymphocyte ratio (≥4), synchronous metastasis, low albumin (<3.0 g/dL), and low hemoglobin (<lower limit of normal: male, 13 g/dL; female, 11.5 g/dL) were the significant factors in 5-year mortality. Good internal validity was demonstrated with area under the curve estimates being 0.774 at 5-year mortality calculation and the calibration plot. In the external validation, 758 (82.8%) died by 5 years among these patients, with the average model-predicted rate of 72.9%. CONCLUSIONS: A clinical calculator has been developed to quantify the risk of death for individual patients after treatment of mRCC. This tool may be useful for patients or their guardians who want to know their prognosis and to identify patients requiring aggressive therapy and additional supportive measures during and after treatment.
format Online
Article
Text
id pubmed-7189103
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Korean Urological Association
record_format MEDLINE/PubMed
spelling pubmed-71891032020-05-06 Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database Park, Jae Young Tae, Bum Sik Jeong, Chang Wook Song, Cheryn Seo, Seong Il Hong, Sung Kyu Chung, Jinsoo Hong, Sung-Hoo Hwang, Eu Chang Kwak, Cheol Seo, Ill Young Park, Suyeon Park, Chanwang Investig Clin Urol Original Article PURPOSE: To develop the clinical calculator for mortality of patients with metastatic renal cell carcinoma (mRCC) using Korean Renal Cancer Study Group (KRoCS) database. MATERIALS AND METHODS: Data from 1,115 patients with mRCC treated in 4 hospitals joining KRoCS between 1993 and 2016 were pooled. Five-year survival rates were calculated using Kaplan–Meier curve. A clinical calculator for 5-year mortality was developed using multivariable logistic regression analysis and validated externally using dataset including 916 patients from 4 other hospitals. RESULTS: Overall survival rates and cancer specific survival rate at 5 years were 28.5% and 29.4%, respectively. Among baseline factors, increased neutrophil-lymphocyte ratio (≥4), synchronous metastasis, low albumin (<3.0 g/dL), and low hemoglobin (<lower limit of normal: male, 13 g/dL; female, 11.5 g/dL) were the significant factors in 5-year mortality. Good internal validity was demonstrated with area under the curve estimates being 0.774 at 5-year mortality calculation and the calibration plot. In the external validation, 758 (82.8%) died by 5 years among these patients, with the average model-predicted rate of 72.9%. CONCLUSIONS: A clinical calculator has been developed to quantify the risk of death for individual patients after treatment of mRCC. This tool may be useful for patients or their guardians who want to know their prognosis and to identify patients requiring aggressive therapy and additional supportive measures during and after treatment. The Korean Urological Association 2020-05 2020-03-10 /pmc/articles/PMC7189103/ /pubmed/32377601 http://dx.doi.org/10.4111/icu.2020.61.3.260 Text en © The Korean Urological Association, 2020 http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Park, Jae Young
Tae, Bum Sik
Jeong, Chang Wook
Song, Cheryn
Seo, Seong Il
Hong, Sung Kyu
Chung, Jinsoo
Hong, Sung-Hoo
Hwang, Eu Chang
Kwak, Cheol
Seo, Ill Young
Park, Suyeon
Park, Chanwang
Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database
title Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database
title_full Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database
title_fullStr Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database
title_full_unstemmed Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database
title_short Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database
title_sort development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: an analysis of patients from korean renal cancer study group database
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189103/
https://www.ncbi.nlm.nih.gov/pubmed/32377601
http://dx.doi.org/10.4111/icu.2020.61.3.260
work_keys_str_mv AT parkjaeyoung developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase
AT taebumsik developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase
AT jeongchangwook developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase
AT songcheryn developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase
AT seoseongil developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase
AT hongsungkyu developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase
AT chungjinsoo developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase
AT hongsunghoo developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase
AT hwangeuchang developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase
AT kwakcheol developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase
AT seoillyoung developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase
AT parksuyeon developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase
AT parkchanwang developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase
AT developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase